Expression of Microphthalmia Transcription Factor in Sentinel Lymph Nodes of Patients with Melanoma
Minia Hellan, Michelle S. Gentile, Luay Ailabouni, George I. Salti
DOI: 10.4236/jct.2011.22035   PDF    HTML     4,536 Downloads   8,106 Views  


Background: Sentinel lymph node biopsy is widely used in the management of melanoma patients. Multiple markers are used to stain sentinel lymph node tissue including S100, HMB-45 and melan A with different success. We investigated, for the first time, the use of Microphthalmia transcription factor (Mitf) staining in a larger series of sentinel lymph nodes. Mitf is a transcription factor essential for the development and survival of melanocytes. It has been introduced recently as a sensitive and specific marker for melanomas. Methods: Thirty patients with cutaneous melanoma were included in our study: twenty patients underwent sentinel lymph node biopsy; ten patients underwent complete lymph node dissection for clinically positive disease. Results: Ten out of twenty sentinel lymph nodes were negative for tumor cells and showed no Mitf staining. Out of the ten positive sentinel lymph nodes, eight were also positive for Mitf. Only four out of the ten clinically positive lymph nodes stained for Mitf. Conclusions: We conclude that Mitf can be used as an additional marker for evaluating sentinel lymph nodes in patients with melanoma. In addition, our results imply that Mitf is involved in melanoma differentiation.

Share and Cite:

M. Hellan, M. Gentile, L. Ailabouni and G. Salti, "Expression of Microphthalmia Transcription Factor in Sentinel Lymph Nodes of Patients with Melanoma," Journal of Cancer Therapy, Vol. 2 No. 2, 2011, pp. 276-280. doi: 10.4236/jct.2011.22035.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] M. C. Kelley, D. W. Ollila and D. L. Morton, “Lymphatic Mapping and Sentinel Lymphadenectomy for Melanoma,” Seminars in Surgical Oncology, Vol. 14, No. 4, 1998, pp. 283-290. doi:10.1002/(SICI)1098-2388(199806)14:4<283::AID-SSU4>3.0.CO;2-Z
[2] J. E. Gershenwald, W. Thompson, P. F. Mansfield, J. E. Lee, M. I. Colome, C. H. Tseng, et al., “Multi-Institutional Melanoma Lymphatic Mapping Experience: The Prognostic Value of Sentinel Lymph Node Status in 612 Stage I or II Melanoma Patients,” Journal of Clinical Oncology, Vol. 17, No. 3, 1999, pp. 976-983.
[3] C. M. Balch, S. J. Soong, J. E. Gershenwald, J. F. Thompson, D. S. Reintgen, N. Cascinelli, et al. “Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System,” Journal of Clinical Oncology, Vol. 19, No. 16, 2001, pp. 3622-3634.
[4] C. M. Balch, S. J. Soong, M. B. Atkins, A. C. Buzaid, N. Cascinelli, D. G. Coit et al. “An Evidence-Based Staging System for Cutaneous Melanoma,” CA: A Cancer Journal for Clinicians, Vol. 54, No. 3, 2004, pp. 131-149. doi:10.3322/canjclin.54.3.131
[5] A. J. Cochran, B. R. Balda, H. Starz, D. Bachter, D. N. Krag, C. W. Cruse, et al., “The Augsburg Consensus. Techniques of Lymphatic Mapping, Sentinel Lymphade- nectomy, and Completion Lymphadenectomy in Cutaneous Malignancies,” Cancer, Vol. 89, No. 2, 2000, pp. 236-241. doi:10.1002/1097-0142(20000715)89:2<236::AID-CNCR5>3.0.CO;2-0
[6] M. V. Sheffield, H. Yee, C. C. Dorvault, K. N. Weil- baecher, I. A. Eltoum, G. P. Siegal et al. “Comparison of Five Antibodies as Markers in the Diagnosis of Melanoma in Cytologic Preparations,” American Journal of Clinical Pathology, Vol. 118, No. 6, 2002, pp. 930-936. doi:10.1309/EWK9-LUPR-6BC5-1GXV
[7] M. Miettinen, M. Fernandez, K. Franssila, Z. Gatalica, J. Lasota and M. Sarlomo-Rikala, “Microphthalmia Transcription Factor in the Immunohistochemical Diagnosis of Metastatic Melanoma: Comparison with Four Other Melanoma Markers,” The American Journal of Surgical Pathology, Vol. 25, No. 2, 2001, pp. 205-211. doi:10.1097/00000478-200102000-00008
[8] K. Blessing, D. S. Sanders and J. J. Grant, “Comparison of Immunohistochemical Staining of the Novel Antibody Melan-A with S100 Protein and HMB-45 in Malignant Melanoma and Melanoma Variants,” Histopathology, Vol. 32, No. 2, 1998, pp. 139-146. doi:10.1046/j.1365-2559.1998.00312.x
[9] G. I. Salti, T. Manougian, M. Farolan, A. Shilkaitis, D. Majumdar and T. K. Das Gupta, “Micropthalmia Transcription Factor: A New Prognostic Marker in Intermediate-Thickness Cutaneous Malignant Melanoma,” Cancer Research, Vol. 60, No. 18, 2000, pp. 5012-5016.
[10] R. King, K. N. Weilbaecher, G. McGill, E. Cooley, M. Mihm and D. E. Fisher, “Microphthalmia Transcription Factor. A Sensitive and Specific Melanocyte Marker for Melanoma Diagnosis,” American Journal of Pathology, Vol. 155, No. 3, 1999, pp. 731-738. doi:10.1016/S0002-9440(10)65172-3
[11] R. King, P. B. Googe, K. N. Weilbaecher, M. C. Mihm Jr and D. E. Fisher, “Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors,” The American Journal of Surgical Pathology, Vol. 25, No. 1, 2001, pp. 51-57. doi:10.1097/00000478-200101000-00005
[12] E. Steingrimsson, N. G. Copeland and N. A. Jenkins, “Melanocytes and the Microphthalmia Transcription Factor Network,” Annual Review of Genetics, Vol. 38, 2004, pp. 365-411.
[13] S. R. Granter, K. N. Weilbaecher, C. Quigley and D. E. Fisher, “Role for Microphthalmia Transcription Factor in the Diagnosis of Metastatic Malignant Melanoma,” Applied Immunohistochemistry & Molecular Morphology, Vol. 10, No. 1, 2002, pp. 47-51. doi:10.1097/00022744-200203000-00008
[14] C. C. Dorvault, K. N. Weilbaecher, H. Yee, D. E. Fisher, L. A. Chiriboga, Y. Xu and D. C. Chhieng, “Microph- thalmia Transcription Factor: A Sensitive and Specific Marker for Malignant Melanoma in Cytologic Specimens,” Cancer, Vol. 93, No. 5, 2001, pp. 337-343. doi:10.1002/cncr.9049
[15] F. M. O’Reilly, D. J. Brat, B. E. McAlpine, H. E. Grossniklaus, A. L. Folpe and J. L. Arbiser, “Microphthalmia Transcription Factor Immunohistochemistry: A Useful Diagnostic Marker in the Diagnosis and Detection of Cutaneous Melanoma, Sentinel Lymph Node Metastases, and Extracutaneous Melanocytic Neoplasms,” Journal of the American Academy of Dermatology, Vol. 45, No. 3, 2001, pp. 414-419. doi:10.1067/mjd.2001.117526
[16] I. A. Jacobs, C. K. Chang, T. K. Das Gupta and G. I. Salti, “Role of Sentinel Lymph Node Biopsy in Patients with Thin (< 1 mm) Primary Melanoma,” Annals of Surgical Oncology, Vol. 10, No. 5, 2003, pp. 558-561. doi:10.1245/ASO.2003.10.025
[17] C. A. Hodgkinson, K. J. Moore, A. Nakayama, E. Steingrimsson, N. G. Copeland, N. A. Jenkins, et al., “Mutations at the Mouse Microphthalmia Locus are Associated with Defects in a Gene Encoding a Novel Basic-Helix- Loop-Helix-Zipper Protein,” Cell, Vol. 74, No. 2, 1993, pp. 395-404. doi:10.1016/0092-8674(93)90429-T
[18] C. A. Ferguson and S. H. Kidson, “The Regulation of Tyrosinase Gene Transcription,” Pigment Cell Research, Vol. 10, No. 3, 1997, pp. 127-138. doi:10.1111/j.1600-0749.1997.tb00474.x
[19] C. R. Goding, “Mitf from Neural Crest to Melanoma: Signal Transduction and Transcription in the Melanocyte Lineage,” Genes & Development, Vol. 14, No. 14, 2000, pp. 1712-1728.
[20] M. B. Koch, I. M. Shih, S. W. Weiss and A. L. Folpe, “Microphthalmia Transcription Factor and Melanoma Cell Adhesion Molecule Expression Distinguish Desmoplastic/Spindle Cell Melanoma from Morphologic Mimics,” The American Journal of Surgical Pathology, Vol. 25, No. 1, 2001, pp. 58-64. doi:10.1097/00000478-200101000-00006
[21] S. R. Granter, K. N. Weilbaecher, C. Quigley, C. D. Fletcher and D. E. Fisher, “Microphthalmia Transcription Factor: Not a Sensitive or Specific Marker for the Diagnosis of Desmoplastic Melanoma and Spindle Cell (Non-Desmoplastic) Melanoma,” The American Journal of Dermatopathology, Vol. 23, No. 3, 2001, pp. 185-189. doi:10.1097/00000372-200106000-00004
[22] K. J. Busam, K. Iversen, K. C. Coplan and A. A. Jungbluth, “Analysis of Microphthalmia Transcription Factor Expression in Normal Tissues and Tumors, and Comparison of Its Expression with S-100 Protein, gp100, and Tyrosinase in Desmoplastic Malignant Melanoma,” The American Journal of Surgical Pathology, Vol. 25, No. 2, 2001, pp. 197-204. doi:10.1097/00000478-200102000-00007
[23] J. M. Ranieri, J. D. Wagner, R. Azuaje, D. Davidson, S. Wenck, J. Fyffe et al. “Prognostic Importance of Lymph Node Tumor Burden in Melanoma Patients Staged by Sentinel Node Biopsy,” Annals of Surgical Oncology, Vol. 9, No. 10, 2002, pp. 975-981. doi:10.1007/BF02574515
[24] E. Selzer, V. Wacheck, T. Lucas, E. Heere-Ress, M. Wu, K. N. Weilbaecher et al. “The Melanocyte-Specific Isoform of the Microphthalmia Transcription Factor Affects the Phenotype of Human Melanoma,” Cancer Research, Vol. 62, No. 7, 2002, pp. 2098-2103.
[25] F. Lekmine, N. Sethakorn, C. K. Chang, T. K. Das Gupta and G. I. Salti, “Role of Microphthalmia-Associated Trans- cription Factor (Mitf) in Melanoma Differentiation,” Biochemical and Biophysical Research, Vol. 354, No. 3, 16 March 2007, pp. 830-835. doi:10.1016/j.bbrc.2007.01.075

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.